Discover investment opportunities in Good Pharma Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Good Pharma Stocks To Buy using our Smart AI Filter.
AI is processing your request...
Scanning thousands of stocks to find the best matches...
Discover investment opportunities in Good Pharma Stocks To Buy using our Smart AI Filter.
10 stocks found for "Good Pharma Stocks To Buy"
Security name | Expected returns | Sharpe Ratio | Beta | Volatility | P/E Ratio | Dividend Yield |
|---|---|---|---|---|---|---|
0.30 Risk measure | ±26.0% Price volatility | 12.1 Valuation | 0.66% Annual yield | |||
0.37 Risk measure | ±19.7% Price volatility | 14.7 Valuation | 3.18% Annual yield | |||
0.59 Risk measure | ±31.6% Price volatility | 34.5 Valuation | 0.77% Annual yield | |||
0.35 Risk measure | ±28.9% Price volatility | 6.7 Valuation | 5.29% Annual yield | |||
0.32 Risk measure | ±24.8% Price volatility | 8.7 Valuation | 6.75% Annual yield | |||
0.22 Risk measure | ±27.3% Price volatility | 15.0 Valuation | 2.83% Annual yield | |||
0.36 Risk measure | ±26.9% Price volatility | 24.5 Valuation | 0.00% Annual yield | |||
0.60 Risk measure | ±27.2% Price volatility | 15.6 Valuation | 3.47% Annual yield | |||
0.33 Risk measure | ±27.9% Price volatility | 8.6 Valuation | 4.00% Annual yield | |||
0.45 Risk measure | ±20.5% Price volatility | 12.7 Valuation | 3.02% Annual yield |
This search uses our Smart AI Filter to identify stocks matching your criteria. Results are ranked by relevance and include key financial metrics to help you make informed investment decisions.
Get personalized stock recommendations, save custom screens, and access premium filters. All our screening tools are free—signing up gives you more personalized results and the ability to save your research.
Compliance disclosure:
The securities listed on this website have not paid to be included in the results. The inclusion of any securities in the results shown does not imply any relationship with PortfolioPilot. The order of the results is ranked based on the Sharpe Ratio, which is a measure of risk-adjusted return. Please note that these listings are not recommendations or financial advice. Past performance is not indicative of future results.
Some investors follow company insiders on the notion that they would know better than anyone when it's the right time to buy or sell shares. CNBC rounded up some of the biggest sales over the last week.
Read moreEylea's sales slump and pipeline setbacks have dragged REGN down 22.8% YTD, underperforming its peers and the S&P 500.
Read moreRecently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Read moreBristol Myers Squibb and Pfizer said they will start selling their blockbuster blood thinner, Eliquis, directly to some patients at a more than 40% discount. The companies' new effort would bypass traditional middlemen, including pharmacy benefit managers and insurers, to cut the drug's monthly cost from a list price of around $606 to $346.
Read moreTrump's "big beautiful" bill will also affect the pharmaceutical industry, while AI startups have pulled in the majority of digital health funding this year.
Read moreJared Holxz, Mizuho, joins 'Fast Money' to talk competition in the obesity drug space.
Read more